Additionally, the use of optimal background HF therapy, including beta-blockers, mineralocorticoid receptor antagonists, sodium-glucose transporter-2 inhibitors, and diuretics, may account for an overall low CV-related mortality event rate in the SAV and ACEI/ARBs groups.29 The gene discussed is NR3C2; the disease is hydrops fetalis.